Moreover, current research indicates their involvement in cancer therapy as drugs targeting oncogenic signaling in tumor cells through c-MET, a receptor tyrosine kinase, not only impedes tumor progression but also blocks neutrophil recruitment into tumors and the draining lymph nodes. This evidence concerns the gene NTRK1 and cancer.